In stunning reversal, Takeda snags FDA approval for once-snubbed Eohilia after ‘significant grassroots support’
Fierce Pharma
FEBRUARY 12, 2024
Eohilia, an oral suspension formulation of the corticosteroid budesonide, has surprisingly won over the FDA even after the drug’s developer, Takeda, had at one point abandoned the program following | Takeda's Eohilia has surprisingly won over the FDA even after the company had at one point abandoned the program following an FDA rejection.
293 
Let's personalize your content